BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15459602)

  • 21. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study.
    Jo SH; Koo BK; Park JS; Kang HJ; Cho YS; Kim YJ; Youn TJ; Chung WY; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2008 Mar; 155(3):499.e1-8. PubMed ID: 18294484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
    Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
    Trials; 2009 Jun; 10():45. PubMed ID: 19563648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
    Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
    JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography.
    Durham JD; Caputo C; Dokko J; Zaharakis T; Pahlavan M; Keltz J; Dutka P; Marzo K; Maesaka JK; Fishbane S
    Kidney Int; 2002 Dec; 62(6):2202-7. PubMed ID: 12427146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sodium bicarbonate plus N-acetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (BIcarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study.
    Leone AM; De Caterina AR; Sciahbasi A; Aurelio A; Basile E; Porto I; Trani C; Burzotta F; Niccoli G; Mongiardo R; Mazzari MA; Buffon A; Panocchia N; Romagnoli E; Lioy E; Rebuzzi AG; Crea F
    EuroIntervention; 2012 Nov; 8(7):839-47. PubMed ID: 23171803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
    Hafiz AM; Jan MF; Mori N; Shaikh F; Wallach J; Bajwa T; Allaqaband S
    Catheter Cardiovasc Interv; 2012 May; 79(6):929-37. PubMed ID: 21542114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention.
    Jabara R; Gadesam RR; Pendyala LK; Knopf WD; Chronos N; Chen JP; Viel K; King SB; Manoukian SV
    Am J Cardiol; 2009 Jun; 103(12):1657-62. PubMed ID: 19539072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.
    Chen SL; Zhang J; Yei F; Zhu Z; Liu Z; Lin S; Chu J; Yan J; Zhang R; Kwan TW
    Int J Cardiol; 2008 Jun; 126(3):407-13. PubMed ID: 17651830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. N-acetylcysteine and sodium bicarbonate versus N-acetylcysteine and standard hydration for the prevention of radiocontrast-induced nephropathy following coronary angiography.
    Schmidt P; Pang D; Nykamp D; Knowlton G; Jia H
    Ann Pharmacother; 2007 Jan; 41(1):46-50. PubMed ID: 17190844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
    Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
    Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?
    Kefer JM; Hanet CE; Boitte S; Wilmotte L; De Kock M
    Acta Cardiol; 2003 Dec; 58(6):555-60. PubMed ID: 14713182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
    Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
    J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of hydration with or without n-acetylcysteine on contrast induced nephropathy in patients undergoing coronary angiography and percutaneous coronary intervention.
    Awal A; Ahsan SA; Siddique MA; Banerjee S; Hasan MI; Zaman SM; Arzu J; Subedi B
    Mymensingh Med J; 2011 Apr; 20(2):264-9. PubMed ID: 21522098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT).
    ACT Investigators
    Circulation; 2011 Sep; 124(11):1250-9. PubMed ID: 21859972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions.
    Buyukhatipoglu H; Sezen Y; Yildiz A; Bas M; Kirhan I; Ulas T; Turan MN; Taskin A; Aksoy N
    Pol Arch Med Wewn; 2010 Oct; 120(10):383-9. PubMed ID: 20980943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.